peptone.ioCrawled Nov 1, 2026
A small molecule that binds monomeric alpha-synuclein and biases its conformational ensemble away from the aggregation pathway implicated in Parkinson's disease.
A small molecule that engages the intrinsically disordered N-terminal domain of the androgen receptor to shut down transcriptional signalling that current therapies leave intact.
A lead optimization program developing an antagonist of the intrinsically disordered transcription factor c-Myc, advanced with UCL Cancer Institute disease biology.
Peptone’s small-molecule pipeline targets intrinsically disordered proteins, with programs progressing from discovery to clinical stages.
A Nature Communications study from Peptone and the University of Copenhagen shows how multithermal enhanced sampling reveals rare, experimentally consistent ACTR states.
Peptone presented its Kubernetes and AWS architecture for protein structure prediction to more than 8,000 attendees at KubeCon + CloudNativeCon Europe 2025.
Biopharmaceutical dealmaker Dr. George Golumbeski joined Peptone as a Board and Executive Advisor.
Peptone founder and CEO Dr. Kamil Tamiola joined the Scientific Advisory Board of ELIXIR CZ, the Czech national infrastructure for biological data.
Dr. Patrick Kunz joined Peptone as Head of Experimental Biophysics, bringing experience in protein analytics and biologics formulation development.
Culture and careers at Peptone: honest science, kindness, and good spirit, in service of the patients waiting on it.
Alex Bisioti directs business development and corporate strategy at Peptone, focusing on small-molecule drug discovery.
Alice Santopolo works as a research associate in cell biology and functional screenings at Peptone, contributing to small-molecule drug discovery.
Dr. Alex Pasteur is Venture Capital Investor at Peptone, building a Product Engine for small-molecule drug discovery against intrinsically disordered proteins.
Peptone’s leadership team, Board, and Scientific Advisory Board include experts in drug discovery, company-building, and specialist scientific fields.
Peptone’s mission, team, culture, leadership, and investors drive its Product Engine for intrinsically disordered protein drug discovery.
Peptone accepts inquiries about scientific partnerships, careers, business development, and general contact across its European and United States teams.
Peptone is building a Product Engine to generate small-molecule drug candidates against intrinsically disordered proteins.
How Peptone processes personal data submitted by candidates during recruitment in Switzerland and the United Kingdom.
